# US 2024/0409606 A1 · T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0409606 A1
- Document ID: US20240409606A1
- Status: Published application
- Kind: A1
- Application number: 18/656,531
- Filed: 2024-05-06
- Published: 2024-12-12
- Earliest claimed: 2017-09-07
- Assignees: Cue Biopharma, Inc.
- Applicants: Cue Biopharma, Inc.
- Inventors: Ronald D. SEIDEL, III; Rodolfo J. CHAPARRO; John F. ROSS; Chee Meng LOW
- Web page: https://patentgrep.com/patent/US20240409606A1

## CPC

- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/16: acting on ester bonds (3.1)
- C12Y 301/06: Sulfuric ester hydrolases (3.1.6)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/605: {MHC molecules or ligands thereof}
- A61K 2039/64: {characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 2710/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16133: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2730/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2730/10133: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present disclosure provides T-cell modulatory multimeric polypeptides (“T-Cell-MMPs”) comprising an immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”) and a location for covalently attaching a molecule that can serve as an epitope, such as an epitope peptide. Once the epitope molecule is attached the resulting T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for IL-2R, to the T-cells in an epitope selective/specific manner, and accordingly, for modulating an immune response in an individual.

## Claims

### Claim at position 1

-19. (canceled)

### Claim 20

A T-cell modulatory multimeric polypeptide epitope conjugate (T-Cell-MMP-epitope conjugate), comprising a T-Cell-MMP and an epitope conjugated thereto, wherein:
the T-Cell-MMP comprises:
a) a first polypeptide comprising
i) a first major histocompatibility complex (MHC) polypeptide having an N-terminus and a C-terminus, wherein the first MHC polypeptide comprises a beta-2-microglobulin (β2M) polypeptide amino acid sequence, and
(ii) a first polypeptide chemical conjugation site that is within the β2M polypeptide amino acid sequence;
b) a second polypeptide having an N-terminus and a C-terminus comprising, in order from N-terminus to C-terminus,
(i) a second MHC polypeptide, wherein the second MHC polypeptide comprises a class I MHC heavy chain polypeptide amino acid sequence comprising a binding pocket;
(ii) optionally a peptide linker amino acid sequence; and
(iii) optionally an immunoglobulin (Ig) Fc polypeptide or a non-Ig polypeptide scaffold amino acid sequence;
c) a molecule presenting a peptide or non-peptide epitope that is covalently bound, either directly or indirectly through a linker, to the first polypeptide chemical conjugation site, wherein the molecule comprising the epitope is positioned in the binding pocket of the T-Cell MMP for presentation to a cell bearing a T-cell receptor specific for the epitope presented by the epitope peptide; and
d) one or more immunomodulatory polypeptide amino acid sequences (MODs), wherein at least one of the one or more MODs is
i) at the C-terminus of the first polypeptide,
ii) at the N-terminus of the second polypeptide,
iii) at the C-terminus of the second polypeptide, or
iv) at the C-terminus of the first polypeptide and at the N-terminus of the second polypeptide;
wherein each of the one or more MODs is an independently selected wild-type or variant MOD.

### Claim 21 (depends on 20)

The T-Cell-MMP-epitope conjugate of claim 20, wherein the second polypeptide comprises an immunoglobulin (Ig) Fc polypeptide or a non-Ig polypeptide scaffold.

### Claim 22 (depends on 20)

The T-Cell-MMP-epitope conjugate of claim 20, wherein:
the T-Cell-MMP comprises one or more independently selected variant MOD polypeptides;
at least one of the one or more variant MOD polypeptides exhibits a reduced affinity to its Co-MOD compared to the affinity of a corresponding wild-type MOD for the Co-MOD; and
the ratio of i) the binding affinity of a control T-Cell-MMP-epitope conjugate to a Co-MOD to ii) the binding affinity of a T-Cell-MMP-epitope conjugate comprising a variant of the wild-type MOD to the Co-MOD, when measured by bio-layer interferometry (“BLI”), is at least 1.5:1 or in a range of from 1.5:1 to 106:1.

### Claim 23 (depends on 20)

The T-Cell-MMP-epitope conjugate of claim 20, wherein the wild-type MOD polypeptides are selected independently from the group consisting of IL-2, 4-1BBL, PD-L1, CD70, CD80, CD86, ICOS-L, OX-40L, FasL, JAG1, TGFβ, ICAM, and PD-L2, and the variant MOD polypeptides are variants thereof.

### Claim 24 (depends on 20)

The T-Cell-MMP-epitope conjugate of claim 20, wherein the first polypeptide chemical conjugation site is selected from:
peptide sequences that act as an enzymatic modification sequence;
non-natural amino acids and/or selenocysteines;
engineered amino acid chemical conjugation sites;
carbohydrate or oligosaccharide moieties; and/or
IgG nucleotide binding sites.

### Claim 25 (depends on 24)

The T-Cell-MMP-epitope conjugate of claim 24, wherein the first polypeptide chemical conjugation site comprises an engineered amino acid chemical conjugation site.

### Claim 26 (depends on 25)

The T-Cell-MMP-epitope conjugate of claim 25, wherein the engineered amino acid chemical conjugation site comprises a cysteine.

### Claim 27 (depends on 24)

The T-Cell-MMP-epitope conjugate of claim 24, wherein:
the first polypeptide chemical conjugation site comprises a cysteine;
the β2M polypeptide sequence has at least 90% amino acid sequence identity to amino acids 21-119 of any one of SEQ ID NOs:151-155; and
the class I MHC heavy chain polypeptide has at least 90% sequence identity to at least 250 contiguous amino acids of an MHC heavy chain sequence set forth in any one of SEQ ID NOs:134-150.

### Claim 28 (depends on 26)

The T-Cell-MMP-epitope conjugate of claim 26, wherein:
the first polypeptide chemical conjugation site comprises a cysteine;
the β2M polypeptide sequence has at least 90% amino acid sequence identity to amino acids 21-119 of any one of SEQ ID NOs:151-155; and
the class I MHC heavy chain polypeptide has at least 90% sequence identity to at least 250 contiguous amino acids of an MHC heavy chain sequence set forth in any one of SEQ ID NOs:134-150.

### Claim 29 (depends on 27)

The T-Cell-MMP-epitope conjugate of claim 27, wherein the epitope is an epitope of a cancer associated antigen, a viral epitope, or an epitope of a self antigen.

### Claim 30 (depends on 28)

The T-Cell-MMP-epitope conjugate of claim 28, wherein the epitope is an epitope of a cancer associated antigen, a viral epitope, or an epitope of a self antigen.

### Claim 31 (depends on 30)

The T-Cell-MMP-epitope conjugate of claim 30, wherein the at least one or more MODs comprises an IL-2 polypeptide comprising the amino acid sequence: APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML TFKFYMPKKA TELKHLQCLEEELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNRWITFCQSIIS TLT (SEQ ID NO:27); or an amino acid sequence having at least 95% sequence identity to SEQ ID NO:27, where the histidine at position 16 is optionally substituted by any amino acid other than histidine, and the phenylalanine at position 42 is substituted by any amino acid other than phenylalanine.

### Claim 32 (depends on 20)

A composition comprising:
a) the T-Cell-MMP-epitope conjugate of claim 20; and
b) a pharmaceutically acceptable excipient.

### Claim 33 (depends on 20)

A method of treatment comprising administering to an individual a T-Cell-MMP-epitope conjugate of claim 20.

### Claim 34 (depends on 28)

A method of treatment comprising administering to an individual a T-Cell-MMP-epitope conjugate of claim 28.

### Claim 35 (depends on 29)

A method of treatment comprising administering to an individual a T-Cell-MMP-epitope conjugate of claim 29.

### Claim 36 (depends on 30)

A method of treatment comprising administering to an individual a T-Cell-MMP-epitope conjugate of claim 30.

### Claim 37 (depends on 32)

A method of treatment comprising administering to an individual a composition of claim 32.

### Claim 38 (depends on 20)

A nucleic acid encoding the first and/or second polypeptide of the T-Cell-MMP-epitope conjugate of claim 20.

### Claim 39 (depends on 20)

A method of preparing a T-Cell-MMP-epitope conjugate of claim 20, comprising culturing a cell comprising one or more nucleic acids encoding the first and second polypeptides of the T-Cell-MMP, wherein the cell expresses an unconjugated T-Cell-MMP.

### Claim 40 (depends on 39)

A method comprising contacting the unconjugated T-Cell-MMP of claim 39 with a peptide or non-peptide epitope presenting molecule and forming a bond between the peptide or non-peptide epitope presenting molecule and the first polypeptide chemical conjugation site.

### Claim 41 (depends on 40)

The method of claim 40, wherein the bond between the peptide or non-peptide epitope presenting molecule and the first polypeptide chemical conjugation site comprises a cysteine located within the β2M polypeptide, and wherein the β2M polypeptide has at least 90% sequence identity to SEQ ID NO:151.
